|1.||Agarwal, Rajesh: 89 articles (12/2015 - 03/2002)|
|2.||Singh, Rana P: 50 articles (12/2015 - 03/2002)|
|3.||Agarwal, Chapla: 44 articles (11/2015 - 03/2002)|
|4.||Deep, Gagan: 22 articles (12/2015 - 06/2006)|
|5.||Ikejima, Takashi: 20 articles (07/2015 - 09/2006)|
|6.||Onodera, Satoshi: 19 articles (07/2015 - 09/2006)|
|7.||Raina, Komal: 17 articles (07/2014 - 09/2007)|
|8.||Dhanalakshmi, Sivanandhan: 15 articles (04/2007 - 06/2002)|
|9.||Tashiro, Shin-ichi: 14 articles (07/2015 - 09/2006)|
|10.||Tyagi, Alpna: 13 articles (10/2012 - 11/2006)|
09/01/2010 - "Recent preclinical studies have also shown strong efficacy of silibinin to target cancer cell's migratory and invasive characteristics as well as their ability to metastasize to distant organs. "
01/01/2013 - "Overall, these results clearly suggest that the anti-cancer efficacy of silybin could be significantly enhanced through structural modifications, and identify strong anti-cancer efficacy of silybin derivatives, namely DHS, 7OM, and 7OG, signifying that their efficacy and toxicity should be evaluated in relevant pre-clinical cancer models in rodents."
04/01/2007 - "Topical or dietary silibinin treatment caused a strong protection against photocarcinogenesis in terms of delay in tumor appearance, multiplicity, and volume. "
09/01/2004 - "Topical application of silibinin before or immediately after UVB exposure or its dietary feeding resulted in a strong protection against photocarcinogenesis, in terms of tumor multiplicity (60-66%; P < 0.001), tumor volume per mouse (93-97%; P < 0.001) and tumor volume per tumor (80-91%; P < 0.001). "
09/01/2010 - "Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer."
|2.||Prostatic Neoplasms (Prostate Cancer)
02/01/2004 - "Recently, due to its non-toxic and mechanism-based strong preventive/therapeutic efficacy, silibinin has entered in phase I clinical trial in prostate cancer patients."
10/01/2007 - "Recent studies have shown that silibinin induces p21/Cip1 and p27/Kip1 and G1 arrest in different prostate cancer cells irrespective of p53 status; however, biological significance and mechanism of such induction have not been studied. "
09/20/2003 - "In several recent studies, we have shown that silibinin inhibits the growth of human prostate cancer cells (PCA) both in vitro and in vivo. "
09/01/2001 - "Previous studies showed that silibinin (SB), the major active component of SM, could inhibit cell proliferation of a human prostate cancer cell line, LNCaP, by arresting the cell cycle at the G(1) phase without causing cell death. "
12/04/2015 - "Although various evidences showed apoptosis signaling pathways by silibinin, there is no report to address the clearly mechanism of silibinin-induced autophagy in prostate cancer PC-3 cells. "
|3.||Lung Neoplasms (Lung Cancer)
01/01/2013 - "Successful studies conducted so far, have established that silibinin is effective both alone and in combination with other agents (e.g., chemotherapeutic and epigenetic agents) in significantly inhibiting the growth of lung cancer cells. "
01/01/2013 - "In this regard, silibinin, a natural flavonolignan, has been rigorously evaluated for the prevention and growth control of lung cancer through extensive in vitro and in vivo studies. "
01/01/2015 - "Silibinin might be a useful agent for lung cancer patients as a non-toxic complementary approach to alleviate the side effects by thorax irradiation."
01/01/2013 - "Therefore, the present review focuses on encompassing the efficacy and mechanisms of silibinin against lung cancer."
12/01/2010 - "Silibinin selectively reduced the activity of the EGFR family (EGFR, ErbB2, and ErbB3) through the inhibition of receptor dimerization in lung cancer cells with EGFR mutations, but not in those harboring the wild type. "
11/01/2013 - "In the present study, the effects of silibinin on allergic inflammation and its signaling were investigated in the induced human mast cells. "
12/02/2015 - "We herein designed silibinin on 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated skin inflammation to test its inhibitory effects. "
12/02/2015 - "Potent inhibitory effect of silibinin from milk thistle on skin inflammation stimuli by 12-O-tetradecanoylphorbol-13-acetate."
04/01/2015 - "In rats receiving both DI and silibinin, the DI induced changes accounted for less sinusoidal dilatation, vacuolization in the hepatocyte cytoplasm and the inflammation around central vein and portal region (P < 0.05). "
01/01/2013 - "p53-mediated autophagy adjustment is involved in the protection of silibinin against murine dermal inflammation and epidermal apoptosis induced by UVB irradiation."
|5.||Skin Neoplasms (Skin Cancer)
09/01/2012 - "These results suggest that silibinin may be beneficial in the removal of UVA-damaged cells and the prevention of skin cancer."
09/01/2005 - "Overall, the protective efficacy of silibinin against skin cancer is supported by sound mechanistic rationale in animal and cell culture studies, and suggests its potential use for humans."
09/01/2005 - "Mechanisms and preclinical efficacy of silibinin in preventing skin cancer."
05/27/2005 - "Together, these findings suggest that silibinin preferentially activates the DNA-PK-p53 pathway for apoptosis in response to UVB-induced DNA damage, and that this could be a predominant mechanism of silibinin efficacy against UVB-induced skin cancer."
11/24/2015 - "Together, these findings suggest that silibinin's efficacy against UVB-induced photodamage is primarily by inhibiting NER and p53; and these findings further support silibinin's usage as a potential inexpensive, effective, and non-toxic agent for skin cancer chemoprevention. "
|3.||Non-alcoholic Fatty Liver Disease
|9.||Biological Markers (Surrogate Marker)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)